Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Empagliflozin, Dapagliflozin And Canagliflozin Market Size Shifted, And What Is the Outlook Through 2034?
The market for empagliflozin, dapagliflozin and canagliflozin has experienced consistent growth in recent years. The market size is anticipated to expand from $9.64 billion in 2024 to $9.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 2.1%. The historical growth can be linked to the global rise in type 2 diabetes, the heightened understanding of SGLT2 inhibitors’ advantages, the increase in the elderly demographic, a growth in obesity prevalence, and an enhanced focus on individualized medicine.
Expectations are high for stable growth in the market size of empagliflozin, dapagliflozin and canagliflozin in the forthcoming years. It is projected to expand to a total of$10.82 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 2.4%. The reasons behind this predicted growth stretch from a rising demand for oral diabetes drugs, increased funding in diabetes research and the development of new drugs, rising healthcare costs, heightened awareness and diagnosis of pre-diabetes, and an intensified focus on combination therapies. The market trends forecast for this period include advancements in medical technologies, combination therapies, telehealth initiatives, health data analytics, and the protection of patient data.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
What Are the Core Growth Drivers Propelling the Empagliflozin, Dapagliflozin And Canagliflozin Market Forward?
The empagliflozin, dapagliflozin, and canagliflozin market is likely to experience growth due to the increasing incidence of diabetes. Diabetes, characterized by elevated blood sugar levels due to inadequate insulin production or inefficient insulin use, is a persistent health challenge. Factors such as inactive lifestyles, unhealthy eating routines, genetic factors, urbanization, aging populations, limited healthcare access, and global obesity increase have contributed to the escalating prevalence of diabetes. Empagliflozin, dapagliflozin, and canagliflozin are utilized in managing diabetes by reducing blood sugar levels. This is achieved by obstructing sodium-glucose co-transporter-2 (SGLT2) in the kidneys, which facilitates glucose excretion via urine. For example, the National Health Service (NHS) in the UK reported that the number of people under 40 with diabetes has surged from 173,166 in 2022 to 216,440 in 2023, showing a disturbing trend amongst this age group. This rapid increase in diabetes in younger generations evidently signifies that the empagliflozin, dapagliflozin, and canagliflozin market will undoubtedly be stimulated by the rising prevalence of diabetes.
What Segment Types Define the Empagliflozin, Dapagliflozin And Canagliflozin Market Structure?
The empagliflozin, dapagliflozin and canagliflozinmarket covered in this report is segmented –
1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin
2) By Application: Application I; Application II; Application III; Application IV
3) By Channel: Hospital; Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg
2) Dapagliflozin: 5 Mg; 10 Mg
3) Canagliflozin: 100 Mg; 300 Mg
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theEmpagliflozin, Dapagliflozin And Canagliflozin Industry Evolution?
Leading firms in the empagliflozin, dapagliflozin, and canagliflozin markets are prioritizing the development of new offerings, such as treatments for pediatric type-2 diabetes, to cater to a diverse range of patients and widen their influence in diabetes care. The treatment for pediatric Type-2 diabetes involves controlling blood sugar levels through alterations in lifestyle, medications, and occasionally insulin therapy, specifically adjusted for children and teenagers. For example, AstraZeneca, a pharmaceutical corporation based in the UK, announced in June 2024 that Farxiga (dapagliflozin), designed to enhance glycemic control, had been authorized by the US Food and Drug Administration (FDA) for use in pediatric patients aged 10 years and up with type 2 diabetes. This authorization was granted based on the promising results of the T2NOW Phase III clinical trial – one of the most comprehensive studies on pediatric type-2 diabetes to date – which demonstrated that Farxiga significantly lowered HbA1c levels in comparison with a placebo. The safety profile of Farxiga amidst this patient group aligned with the observations in adults with type-2 diabetes. This authorization signifies a significant breakthrough, as oral treatment choices for pediatric type-2 diabetes have been scarce. It also highlights AstraZeneca’s dedication to introducing breakthrough treatments in the fields of cardiovascular, renal, and metabolic diseases.
View the full report here:
What Is the Definition of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
Empagliflozin, dapagliflozin, and canagliflozin are medications classified as sodium-glucose co-transporter-2 (SGLT-2) inhibitors primarily used in treating type 2 diabetes mellitus. These medications are taken orally and are part of a broader diabetes management plan that includes diet, exercise, and other medications as needed.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18350
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model